BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38010951)

  • 1. The future of HOXA- expressing leukemias: Menin inhibitor response and resistance.
    Wenge DV; Armstrong SA
    Curr Opin Hematol; 2024 Mar; 31(2):64-70. PubMed ID: 38010951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic targeting in pediatric acute myeloid leukemia with aberrant HOX/MEIS1 expression.
    Juul-Dam KL; Shukla NN; Cooper TM; Cuglievan B; Heidenreich O; Kolb EA; Rasouli M; Hasle H; Zwaan CM
    Eur J Med Genet; 2023 Dec; 66(12):104869. PubMed ID: 38174649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia.
    Klossowski S; Miao H; Kempinska K; Wu T; Purohit T; Kim E; Linhares BM; Chen D; Jih G; Perkey E; Huang H; He M; Wen B; Wang Y; Yu K; Lee SC; Danet-Desnoyers G; Trotman W; Kandarpa M; Cotton A; Abdel-Wahab O; Lei H; Dou Y; Guzman M; Peterson L; Gruber T; Choi S; Sun D; Ren P; Li LS; Liu Y; Burrows F; Maillard I; Cierpicki T; Grembecka J
    J Clin Invest; 2020 Feb; 130(2):981-997. PubMed ID: 31855575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML.
    Heikamp EB; Henrich JA; Perner F; Wong EM; Hatton C; Wen Y; Barwe SP; Gopalakrishnapillai A; Xu H; Uckelmann HJ; Takao S; Kazansky Y; Pikman Y; McGeehan GM; Kolb EA; Kentsis A; Armstrong SA
    Blood; 2022 Feb; 139(6):894-906. PubMed ID: 34582559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Box of Chemistry to Inhibit the MEN1 Tumor Suppressor Gene Promoting Leukemia.
    Ozyerli-Goknar E; Nizamuddin S; Timmers HTM
    ChemMedChem; 2021 May; 16(9):1391-1402. PubMed ID: 33534953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
    Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R
    Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML.
    Bourgeois W; Cutler JA; Aubrey BJ; Wenge DV; Perner F; Martucci C; Henrich JA; Klega K; Nowak RP; Donovan KA; Boileau M; Wen Y; Hatton C; Apazidis AA; Olsen SN; Kirmani N; Pikman Y; Pollard JA; Perry JA; Sperling AS; Ebert BL; McGeehan GM; Crompton BD; Fischer ES; Armstrong SA
    Blood; 2024 Apr; 143(15):1513-1527. PubMed ID: 38096371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia.
    Candoni A; Coppola G
    Hematol Rep; 2024 Apr; 16(2):244-254. PubMed ID: 38651453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
    Brzezinka K; Nevedomskaya E; Lesche R; Steckel M; Eheim AL; Haegebarth A; Stresemann C
    J Hematol Oncol; 2019 Jun; 12(1):66. PubMed ID: 31253180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia.
    Shi A; Murai MJ; He S; Lund G; Hartley T; Purohit T; Reddy G; Chruszcz M; Grembecka J; Cierpicki T
    Blood; 2012 Nov; 120(23):4461-9. PubMed ID: 22936661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small Molecule Menin Inhibitors: Novel Therapeutic Agents Targeting Acute Myeloid Leukemia with KMT2A Rearrangement or NPM1 Mutation.
    Thomas X
    Oncol Ther; 2024 Mar; 12(1):57-72. PubMed ID: 38300432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
    Dzama MM; Steiner M; Rausch J; Sasca D; Schönfeld J; Kunz K; Taubert MC; McGeehan GM; Chen CW; Mupo A; Hähnel P; Theobald M; Kindler T; Koche RP; Vassiliou GS; Armstrong SA; Kühn MWM
    Blood; 2020 Nov; 136(21):2442-2456. PubMed ID: 32589720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of menin in hematopoiesis.
    Maillard I; Hess JL
    Adv Exp Med Biol; 2009; 668():51-7. PubMed ID: 20175452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Menin Inhibitors in Acute Myeloid Leukemia-What Does the Future Hold?
    Swaminathan M; Bourgeois W; Armstrong SA; Wang ES
    Cancer J; 2022 Jan-Feb 01; 28(1):62-66. PubMed ID: 35072375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias.
    Yi Y; Ge S
    J Hematol Oncol; 2022 Mar; 15(1):35. PubMed ID: 35331314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia.
    Grembecka J; He S; Shi A; Purohit T; Muntean AG; Sorenson RJ; Showalter HD; Murai MJ; Belcher AM; Hartley T; Hess JL; Cierpicki T
    Nat Chem Biol; 2012 Jan; 8(3):277-84. PubMed ID: 22286128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin-MLL Inhibition.
    Soto-Feliciano YM; Sánchez-Rivera FJ; Perner F; Barrows DW; Kastenhuber ER; Ho YJ; Carroll T; Xiong Y; Anand D; Soshnev AA; Gates L; Beytagh MC; Cheon D; Gu S; Liu XS; Krivtsov AV; Meneses M; de Stanchina E; Stone RM; Armstrong SA; Lowe SW; Allis CD
    Cancer Discov; 2023 Jan; 13(1):146-169. PubMed ID: 36264143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. It's All About MEis: Menin-MLL Inhibition Eradicates NPM1-Mutated and MLL-Rearranged Acute Leukemias in Mice.
    Gundry MC; Goodell MA; Brunetti L
    Cancer Cell; 2020 Mar; 37(3):267-269. PubMed ID: 32183947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumorigenicity of Ewing sarcoma is critically dependent on the trithorax proteins MLL1 and menin.
    Svoboda LK; Bailey N; Van Noord RA; Krook MA; Harris A; Cramer C; Jasman B; Patel RM; Thomas D; Borkin D; Cierpicki T; Grembecka J; Lawlor ER
    Oncotarget; 2017 Jan; 8(1):458-471. PubMed ID: 27888797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the undruggable: menin inhibitors ante portas.
    Dempke WCM; Desole M; Chiusolo P; Sica S; Schmidt-Hieber M
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):9451-9459. PubMed ID: 37103568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.